BioMarin Pharmaceutical stock
BMRNNASDAQBioMarin Pharmaceutical Inc., HealthcareISIN US09061G1013
50Score 50 out of 100, Neutral
Price and trend
66 / 100
Price history
+6.2% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.2% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 17% below its 52-week high. Largest decline in 20 years: 75% (February 2008 to March 2009).
Chart figures for advanced users
- SMA 50$59.25
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$58.46
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$49.67
- The lowest closing price of the last twelve months.
- Resistance$70.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BioMarin Pharmaceutical Inc. belongs to the Biotechnology industry (United States) and, with a market value of $11.3B, is number 33 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.22B (up 12.9% year on year) and earnings of $348.9M (down 18.3%).
- For fiscal 2026, analysts expect on average revenue of $3.87B (up 20%) and adjusted earnings per share of $3.00 (up 66.9%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 380 of 714 in Healthcare, median 53.
- Our model puts fair value at $148.70, with the price 61% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 48.8% a year through 2028 (estimates from 15 analysts).
Weaknesses
- Loss-makingLoss of $19.12M over the last 12 months.Fundamentals 27
- Earnings per share fallingDown 17.5% a year since 2020.Growth 46
Its standout strengths are stability and valuation, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 50.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $114.39 and expensive above $212.43 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 10.7%. At 11.7% the fair value would be $127.41, at 9.7% it would be $177.40.
Possible value trap: looks cheap, but weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.1% on the twelve months before. Revenue has grown strongly since 2006, at around 21% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating 17%, net 11%. Last 12 months: net −1%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 2 Nov 2026EPS reported $0.23 (expected −$0.05)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 40.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $3.00−40.2%
- Revenue
- $3.87B−1.0%
- Earnings per share
- $6.36−2.9%
- Revenue
- $4.45B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.5%2026 guidance raised for total revenues, Voxzogo revenue and non-GAAP diluted EPS; Voxzogo is on a path to over $1 billion.
“Each carrying peak revenue potential well above $1 billion and Vimizim is expected to also reach the $1 billion mark over time.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.16M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Davis George EricSale
2 Sept 2026, EVP, Chief Legal Officer
- Shares
- 17,557
- Price
- $66.28
- Value
- $1.16M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BioMarin Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Pharmaron Beijing300759.SZ $12.15B58
- Financière de TubizeTUB.BR $11.9B50
- Halozyme TherapeuticsHALO $11.59B80
- Bio-TechneTECH $11.44B65
- VaxcytePCVX $10.8B46
- Akeso9926.HK $10.58B32
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
- Spyre TherapeuticsSYRE $10.14B48
ETFs that hold BioMarin Pharmaceutical
Held by 20 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.89% | 0.50% | €127.06M |
| L&G Pharma Breakthrough UCITS ETFETLI | 2.13% | 0.49% | €26.29M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.11% | 0.49% | €318.39M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.71% | 0.35% | €1.21B |
| Amundi Global Gender Equality UCITS ETF AccVOOM | 0.58% | 0.20% | €55.72M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.32% | 0.30% | €5.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.14% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.14% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.